The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus
(CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient …

Background. The efficacy of valganciclovir used as preemptive therapy for cytomegalovirus
(CMV) disease in liver transplant recipients is not known. Methods. Between 1996 and 2004 …

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …

Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …

In utilizing a preemptive strategy to minimize the occurrence of symptomatic cytomegalovirus
(CMV) infection following liver transplant, only patients with proven CMV activity by direct …

INTRODUCTION: Cytomegalovirus (CMV) infection after solid organ transplantation is one
of the most common viral infections, causing significant morbidity and mortality if not treated …

Optimal measures for the prevention of cytomegalovirus (CMV) in high‐risk orthotopic liver
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …

Cytomegalovirus (CMV) is one of the most common viral pathogens causing clinical disease
in liver transplant recipients, and contributing to substantial morbidity and occasional …

A retrospective study was performed in liver transplant patients with high risk to develop
cytomegalovirus infection (CMV D+/R−) who were treated with valgancyclovir for 3 months …

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …